VisEn acquires imaging agent portfolio from Bayer
In vivo fluorescence imaging technologies provider VisEn Medical has acquired pharmaceutical manufacturing company Bayer Schering Pharma, Germany’s fluorescence imaging agent intellectual property portfolios and related technology platforms.

The terms of the acquisition include more than 45 patents covering a range of fluorescence agent constructs and imaging methods issued globally, and VisEn's property portfolio covering fluorescence imaging agents will now include more than 150 patents and patent applications, said the Bedford, Mass.-based VisEn.